Overview

  • Product nameAnti-FLAP antibody [EPR5640]
    See all FLAP primary antibodies
  • Description
    Rabbit monoclonal [EPR5640] to FLAP
  • Tested applicationsSuitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    A synthetic peptide corresponding to residues in Human FLAP

  • Positive control
    • Raji, THP-1, HepG2, and K562 cell lysates
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Properties

Applications

Our Abpromise guarantee covers the use of ab124714 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 18 kDa.
  • Application notesIs unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • FunctionRequired for leukotriene biosynthesis by ALOX5 (5-lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic acid, and could play an essential role in the transfer of arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes.
    • Involvement in diseaseGenetic variations in ALOX5AP may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
      Note=Genetic variations in ALOX5AP may be associated with susceptibility to myocardial infarction. Involvement in myocardial infarction is however unclear: according to some authors (PubMed:14770184), a 4-SNP haplotype in ALOX5AP confers risk of myocardial infarction, while according to other (PubMed:17304054) ALOX5AP is not implicated in this condition.
    • Sequence similaritiesBelongs to the MAPEG family.
    • DomainThe C-terminal part after residue 140 is mostly unstructured.
    • Cellular localizationNucleus membrane. Endoplasmic reticulum membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • 5-lipoxygenase activating protein antibody
      • AL5AP_HUMAN antibody
      • ALOX 5AP antibody
      • ALOX5 AP antibody
      • ALOX5AP antibody
      • Arachidonate 5 lipoxygenase activating protein antibody
      • Arachidonate 5-lipoxygenase-activating protein antibody
      • Five lipoxygenase activating protein antibody
      • FLAP antibody
      • MK 886 binding protein antibody
      • MK-886-binding protein antibody
      see all

    Anti-FLAP antibody [EPR5640] images

    • All lanes : Anti-FLAP antibody [EPR5640] (ab124714) at 1/1000 dilution

      Lane 1 : Raji cell lysates
      Lane 2 : THP1 cell lysates
      Lane 3 : HepG2 cell lysates
      Lane 4 : K562 cell lysates

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size : 18 kDa
    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD

    References for Anti-FLAP antibody [EPR5640] (ab124714)

    ab124714 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab124714.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"